GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2007

Vernalis and Servier Research Group Ink Discovery Deal

  • Vernalis and Servier entered into a joint, three-year, oncology drug discovery collaboration. Under the terms of the collaboration, which utilizes Vernalis' drug discovery platform on an undisclosed target, Vernalis will receive an upfront payment and a share in the downstream success of the product.

    "The partnership with Vernalis is a major step in our strategy to increase our efforts in the development of novel anti-cancer therapeutic approaches," remarks Emmanuel Canet, M.D., Ph.D., vp Servier R&D. “This collaboration will expedite the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »